Top Quality Raloxifene hydrochloride Anti Estrogen Steroids

Top Quality Raloxifene hydrochloride Anti Estrogen Steroids

Быстрая деталь:

Наименование товара: ралоксифена гидрохлорид

№ CAS: 82640-04-8

MF: C28H28ClNO4S

МВт: 510.04

Чистота: 99%мин.

Появление: Faint yellow powder

использование : Raloxifene is a selective estrogen receptor modulator (СЭРМ); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.

C21H30O3:

For bodybuilding purposes Adipex-P is often administered during the pre-contest phase of training. When taken in conjunction with all the pre-contest principles that would be employed anyway, i. e. Cardio and weight training exercise, behavioral modification, caloric restriction, increased protein consumption, и т. д., Adipex-P can be a great addition to the carbohydrate craving/depleted diet regimen.

The usual adult dose is one tablet (37.5 мг) daily, administered before breakfast or 1-2 hours after breakfast. Bodybuilder dosage recommendations are consistent with those of patients, and should be individualized to obtain an adequate response with the lowest effective dose. For some patients or bodybuilders half a tablet (18.75 мг) daily may be adequate, while others might take half a dose twice daily. Raloxifene is a selective estrogen receptor modulator (СЭРМ); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.

Raloxifene Adverse reactions

Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, химическое название и суффикс, указывающие на то, что эта форма стероида и полового гормона представляет собой тип спирта, содержащего две гидроксильные группы, can cause developmental abnormalities such as birth defects.

Black box warnings were added to the label of raloxifene in 2007 warning of increased risk of death due to stroke for postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, as well as increased risks for deep vein thrombosis and pulmonary embolism.